Comparison of Clinical Outcomes After Different Surgical Approaches for Lateral Epicondylitis

A Systematic Review and Meta-analysis

Erica Kholinne,^{*†‡} MD, PhD, Leonard Christianto Singjie,^{†§} MD, Maria Anastasia,[†] MD, Felly Liu,[∥] MD, Ira Juliet Anestessia,[‡] MD, Jae-Man Kwak,[¶] MD, PhD, and In-Ho Jeon,[#] MD, PhD Investigation performed at the Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

Background: Lateral epicondylitis (LE) is one of the most common causes of lateral elbow pain. When nonoperative treatment fails, 1 of the 3 surgical approaches—open, percutaneous, or arthroscopic—is used. However, determining which approach has the superior clinical outcome remains controversial.

Purpose: To review the outcomes of different operative modalities for LE qualitatively and quantitatively.

Study Design: Systematic review; Level of evidence, 4.

Methods: This review was performed and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies published in PubMed, Medline (via EBSCO), and ScienceDirect databases that treated LE with open, percutaneous, or arthroscopic approaches with at least 12 months of follow-up were included. Study quality was assessed using the Cochrane Risk of Bias 2 tool and the Methodological Index for Non-Randomized Studies score. The primary outcome was the success rate of each operative treatment approach—open, percutaneous, and arthroscopic.

Results: From an initial search result of 603 studies, 43 studies (n = 1941 elbows) were ultimately included. The arthroscopic approach had the highest success rate (91.9% [95% CI, 89.2%-94.7%]) compared with the percutaneous (91% [95% CI, 87.3%-94.6%]) and open (82.7% [95% CI, 75.6%-89.8%]) approaches for LE surgery with changes in the mean visual analog scale pain score of 5.54, 4.90, and 3.63, respectively. According to the Disabilities of the Arm, Shoulder and Hand score, the functional outcome improved in the arthroscopic group (from 54.11 to 15.47), the percutaneous group (from 44.90 to 10.47), and the open group (from 53.55 to 16.13). The overall improvement was also found in the Mayo Elbow Performance Score, the arthroscopic group (from 55.12 to 90.97), the percutaneous group (from 56.31 to 87.65), and the open group (from 64 to 93.37).

Conclusion: Arthroscopic surgery had the highest rate of success and the best improvement in functional outcomes among the 3 approaches of LE surgery.

Keywords: arthroscopic; lateral epicondylitis; surgical approach; tennis elbow

Lateral epicondylitis (LE)—commonly known as tennis elbow—is one of the most common causes of lateral elbow pain. It is primarily caused by the repetitive strain that leads to the extensor carpi radialis brevis (ECRB) tendon overload. LE can be found in 1% to 3% of the general population and increases in older people, smokers, people who are obese, and those with heavy repetitive activities.⁸

Most LE cases can resolve spontaneously or with conservative treatment. However, up to 10% of patients do not respond to conservative treatment.⁶ Different surgical approaches have been developed for LE. Three approaches are widely used when conservative treatment fails—open, arthroscopic, and percutaneous. However, determining which approach has the superior clinical outcome remains controversial, leaving the option to the individual

The Orthopaedic Journal of Sports Medicine, 12(5), 23259671241230291 DOI: 10.1177/23259671241230291 © The Author(s) 2024

This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (https://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE's website at http://www.sagepub.com/journals-permissions.

surgeon's experience and ease of the approach. 33,39,40,55 Therefore, there is a need to investigate the functional outcomes between these 3 different approaches.

This study aimed to perform a systematic review and meta-analysis to determine whether there is a more successful surgical approach to LE. We hypothesized that among the 3 treatment approaches, arthroscopic surgery would lead to better functional outcomes.

METHODS

Search Strategy

This study was performed and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.⁵² References of included studies were also reviewed to find those not found in the original search. The study protocol was registered on the PROSPERO International Prospective Register of Systematic Reviews. Using the PICO (population, intervention, comparison, and outcomes) model, the study population included patients with chronic LE (persistent lateral elbow pain for >6 months despite conservative treatment); the intervention was any of the 3 surgical treatments (open, percutaneous, or arthroscopic); there was no comparison group; and the outcomes were the success rate and functional outcomes.

A detailed literature search was performed on PubMed, Medline (via EBSCO), and ScienceDirect databases in June 2022 with a Boolean search string consisting of a combination of "lateral epicondylitis," "tennis elbow," "open surgery," "Nirschl procedure," "percutaneous surgery," and "arthroscopic surgery."

Study Selection

All included studies contained original data published in English, treating LE with open, percutaneous, or arthroscopic approaches, with at least 12 months of followup. The success rate of LE surgery was defined as the increment in patient satisfaction, significant improvement in pain, or no need for reintervention. Studies that used adjuvant surgery and additional surgical methods and included patients with previous LE surgery were excluded from the review. Narrative reports, articles on surgical techniques, and animal and cadaveric studies were also excluded.

Level of Evidence and Quality Assessment

Three independent authors (L.C.S., M.A., F.L.) performed identification, selection, data extraction, and level of evidence assessment for each included study. The level of evidence was determined using the 2011 guidelines of the Oxford Centre for Evidence-Based Medicine.²³ The different opinions between the 3 authors were resolved by reassessment and discussion with a fourth author (E.K.). A fifth author (J.M.K.) performed a quality assessment of the studies with the Methodological Index for Non-Randomized Studies (MINORS) score for nonrandomized studies and the Cochrane Risk of Bias 2 assessment tool for randomized studies.^{2,57} The MINORS score allows a maximum of 16 points for noncomparative studies and 24 points for comparative studies. High-quality studies are defined as those with scores of >60%-9 of 16 for noncomparative studies and 14 of 24 for comparative studies.^{31,57} Risk of bias, according to the Cochrane assessment, was judged as high, low, or unclear.^{2,23,57}

Data Extraction and Analysis

All data were extracted from the text, figures, tables, and associated supplementary files from each included study. These data included (1) study and patient characteristics; (2) mean follow-up times; (3) mean LE onset; (4) pain visual analog scale (VAS) scores; (5) functional scores, namely, the Disabilities of the Arm, Shoulder and Hand (DASH) score and the Mayo Elbow Performance Score (MEPS); and (6) the mean duration of return to work. The primary clinical outcome was the success rate of surgery. The secondary outcome was the functional outcome of the patients.

Statistical analysis was performed using the OpenMeta-Analyst (*Tufts Medical Center*). The I^2 value was used to identify the heterogeneity between studies. The randomeffects model was used for all meta-analyses. Forest plots were used to describe the data on surgical success rates. Statistical significance was determined as P < .05.

RESULTS

Study Selection

After the initial screening, 603 studies were retrieved. Of these studies, 43 met the inclusion and exclusion criteria and were ultimately included in this review (Figure 1).

^{*}Address correspondence to Erica Kholinne, MD, PhD, Faculty of Medicine, Universitas Trisakti, Jl. Kyai Tapa No.1, RT.5/RW.9, Tomang, Kec. Grogol petamburan, Kota Jakarta Barat, Daerah Khusus Ibukota, Jakarta, 11440, Indonesia (email: erica@trisakti.ac.id).

[†]Department of Orthopaedic Surgery, Saint Carolus Hospital, Jakarta, Indonesia.

[‡]Faculty Of Medicine, Universitas Trisakti, Jakarta, Indonesia.

[§]Department of Orthopaedic & Traumatology, Hasanuddin University, Makassar, Indonesia.

^{II}Department of Orthopaedic & Traumatology, Padjajaran University, Bandung, Indonesia.

¹Department of Orthopedic Surgery, Uijeongbu Eulji Medical Center, College of Medicine, Eulji University, Uijeongbu, Republic of Korea.

[#]Department of Orthopedic Surgery, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Final revision submitted August 5, 2023; accepted August 18, 2023.

The authors have declared that there are no conflicts of interest in the authorship and publication of this contribution. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.




Figure 1. PRISMA flowchart of study inclusion in the review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Study Quality Assessment

The level of evidence analysis indicated that there were 4 randomized controlled trials,^{11,16,36,38} all with level 2 evidence, and 3 studies^{49,56,59} with level 3 evidence; the remaining 36 studies had level 4 evidence. The 39 non-randomized studies consisted of 35 noncomparative and 4 comparative studies, which, according to the MINORS criteria, were considered to be of high quality (Figure 2). The 4 randomized controlled trials were considered as having a low risk of bias according to the Cochrane Risk of Bias 2 tool.

Characteristics of the Studies and Patients

All studies were published from 2001 to 2022 and included a total of 1941 elbows—609 elbows that underwent open surgery (11 studies** were included in the analysis) (Table 1), 423 elbows that underwent percutaneous surgery (13 studies^{††}) (Table 2), and 909 elbows that underwent arthroscopic surgery (22 studies^{‡‡}) (Table 3). The mean age of the patients varied among the open (range, 41-54.2 years), percutaneous (range, 39-55.3 years), and arthroscopic (range, 33.7-54 years) groups. The duration of LE also varied among the open (range, 13.3-26.4 months), percutaneous (range, >6-40 months), and arthroscopic (range, 6-34 months) groups. The mean follow-up was 7.73 years (range, 1-12.6 years) for the open group, 2.26 years (range, 1-7.5 years) for the percutaneous group, and 3.78 years (range, 1-10.3 years) for the arthroscopic group. The patients in the open group returned to work in 3 weeks to 3 months, the percutaneous group returned in 2 to 3 weeks, and those in the arthroscopic group returned in 6 days to 4.3 months.

Primary Outcome: Surgical Success Rate

The success rate for all 3 surgical approaches was high. The success rate for the open approach was 82.7% (95% CI, 75.6%-89.8%; $I^2 = 86.78\%$; P < .001) (Figure 3A). The success rate for the percutaneous approach was 91% (95% CI, 87.3%-94.6%; $I^2 = 49.41\%$; P = .022) (Figure 3B), and the success rate for the arthroscopic approach was 91.9% (95% CI, 89.2%-94.7%; $I^2 = 56.22\%$; P < .001) (Figure 3C).

Secondary Outcome: Functional Scores

Improvement in the DASH score was shown on all 3 surgical approaches for LE. The arthroscopic approach was found to be superior in improving the pre- to postoperative weighted mean of the DASH score (from 54.51 to 15.47) compared with the percutaneous approach (from 44.90 to 10.47) and the open approach (from 53.55 to 16.13). (Figure 4A). The MEPS also improved on all 3 surgical approaches. It was found that the arthroscopic approach had the most superior pre- to postoperative improvement (from 55.12 to 90.97) compared with the percutaneous (from 56.31 to 87.65) and open approaches (from 64 to 93.37) (Figure 4B).

DISCUSSION

The major finding of our systematic review and metaanalysis of 1941 elbows showed that patients with LE had higher success rates and functional outcomes when treated with an arthroscopic approach than open or percutaneous approaches (91.9% vs 82.7% vs 91%).

Open surgery remains a traditional but preferred method that has lasted almost half a decade. It was first introduced by Nirschl and Pettrone⁴⁶ in 1979 and involved debriding the damaged parts in the insertion of the ECRB muscle by exposing the ECRB, excision of the identified lesion, and repair. Improvement after open surgery has been found in 97.7% of patients and 85.2% of patients returning to full activity. The results in the pilot study by Nirschl and Pettrone⁴⁶ are slightly different from those in our study, where the success rate was 82.7%. The high heterogeneity among the included studies ($I^2 = 86.78\%$) could have influenced the difference in the success rate, considering that the difference in the technique and duration of the follow-up can affect the result. Khashaba²⁸ used

^{**}References 11, 13, 16-18, 37, 38, 58, 59, 63, 66.

⁺⁺References 1, 6, 10, 16, 22, 36, 41, 45, 54, 56, 60, 65, 69.

⁺⁺References 3, 4, 7, 11, 14, 19-21, 24, 27, 35, 36, 43, 44, 48-50, 53, 61, 62, 64, 68.




Figure 2. MINORS Quality Assessment of the 39 nonrandomized studies; 35 studies were noncomparative and 4 studies (indicated with asterisks) were comparative. The vertical red line represents the cutoff point for noncomparative studies to be considered high quality.⁴¹ MINORS, Methodological Index for Non-Randomized Studies.

the standard Nirschl technique without drilling or decortication and reported that at 6 months, the mean extension power was less than that of most unaffected elbows in most patients. On the other hand, Lee et al³⁷ found that the clinical results at a minimum 5-year follow-up revealed statistically significant improved functional scores compared with the preoperative state and muscle strength compared with unaffected elbows.

In the present study, the percutaneous approach, reviewed in 13 studies, was found to have a high success rate (91%). Several surgical techniques regarding the percutaneous approach have been described. The release of extensor tendon origin percutaneously was stated by Cutts et al in their manuscript.¹⁵ A local anesthetic was used in the lateral elbow, and a percutaneous release was performed through a skin incision. The release can be extended by performing the Mill manipulation—full extension with the pronation arm while the wrist and fingers are

held in flexion.^{45,51} Ang et al¹ found that using ultrasound to modify percutaneous surgery resulted in significant pain relief up to 90 months after the surgery. Even with a 3year follow-up, patients with LE experienced considerably improved function and symptoms after an ultrasoundguided percutaneous needle tenotomy. Arthroscopic debridement in LE was first introduced by Baker et al⁵ in 2000 to treat 40 patients. To evaluate intra-articular pathology, Baker et al⁵ classified capsular lesions into 3 types—intact, linear capsular tear, and complete capsular tear. They found that arthroscopic tennis elbow debridement was a reliable treatment, in which 29 of 30 (96.7%) cases were successful.

There is still a lack of evidence to conclude which surgical approach can provide the most superior functional score regarding pain reduction and satisfaction rate. A systematic review by Burn et al⁹ found no significant differences between the 3 surgical techniques (open, arthroscopic,

TABLE 1Characteristics of Studies Using the Open Approach for Lateral Epicondylitis $(n = 11 \text{ Studies})^a$

	Study	MINORS or								Score	e, Preop/Post	op
First Author (Year)	Design; LOE	Cochrane RoB Score	Patients/ Elbows, n	Age, Years	Sex, M/F, n	Onset, Months	Follow-up, Years	Success Rate	RTW, Months	VAS Pain	DASH	MEPS
Lee ³⁷ (2021)	CS; 4	15	99/99	44.8 ± 9.8	39/60	22	8.5	95/99	2.4 ± 0.6	4.9/1.1	50/13	64/90
Clark ¹¹ (2018)	RCT; 2	Low	29/29	46.9 ± 7.04	19/18	_	1	18/29	_	6.13/3.06	46.5/22.2	_
Solheim ⁶³ (2013)	RCC; 4	12	80/80	46	38/42	19	4.1	77/80	_	_	60.5/17.80	_
Dwyer ¹⁸ (2010)	CS; 4	14	22/22	49	12/10	21	2	20/22	3	_	_	_
Coleman ¹³ (2010)	CS; 4	13	137/149	42	72/65	25	9.8	117/137	1.5	_	_	-/95.8
Dunn ¹⁷ (2008)	CS; 4	13	83/92	46	45/38	26.4	12.6	77/92	_	_	_	_
Svernlöv ⁶⁶ (2006)	PCS; 4	12	53/55	46	25/28	33	7.5	46/53	_	_	_	_
Rubenthaler ⁵⁹ (2005)	RC; 3	20^b	10/10	54.2	7/3	13.3	7.625	7/10	0.75			_
Dunkow ¹⁶ (2004)	RCT; 2	Low	24/24	43	11/13	_	1	22/24	5^c		$70^{c}/53^{c}$	_
Rosenberg ⁵⁸ (2002)	CS; 4	14	22/22	47	16/6	21	1	15/19	_			_
Leppilahti ³⁸ $(2001)^d$	RCT; 2	Low	(a) 13/14	(a) 42	(a) 6/7	(a) 23	(a) 2.6	(a) 9/13	(a) 2	_	_	_
			(b) 14/14	(b) 41	(b) 7/7	(b) 23	(b) 2.6	(b) 11/14	(b) 2.5			

^aData are reported as the mean or mean \pm SD unless otherwise indicated. Dashes indicate data not reported. CS, case series; DASH, Disabilities of the Arm, Shoulder and Hand; F, female; LOE, level of evidence; M, male; MEPS, Mayo Elbow Performance Score; PCS, prospective case series; Postop, postoperative; Preop, preoperative; RC, retrospective cohort; RCC, retrospective case control; RCT, randomized controlled trial; RoB, risk of bias; RTW, return to work; VAS, visual analog scale.

^bComparative study.

 c Median.

 d Group (a) underwent decompression of the posterior interosseous nerve; group (b) underwent lengthening of the tendon of the distal tendon of the extensor carpi radialis brevis.

			0					-	•			
	Study	MINORS or								Sco	re, Preop/Po	stop
First Author (Year)	Design; LOE	Cochrane RoB Score	Patients/ Elbows, n	Age, Years	Sex, M/F, n	Onset, Months	Follow-up, Years	Success Rate	RTW, Months	VAS Pain	VAS Pain	VAS Pain
Ang ¹ (2021)	CS; 4	11	19/19	46	7/12	_	7.5	19/19	_	5.5/0	24.2/0.8	_
Yigit ⁶⁹ (2020)	CS; 4	14	41/47	46	19/22	_	4.3	36/41	0.5	-/2.6		/82
Suzuki ⁶⁵ (2020)	CS; 4	10	36/36	55	19/17	10	1	31/36	_	7/3		_
Seng ⁶⁰ (2016)	CS; 4	14	20/20	45.5	7/13	12.5	3	20/20	_	5.4/0.4	27.8/0.4	_
Barnes ⁶ (2015)	CS; 4	14	19/19	55.3	10/9	_	1	15/19	_	6.4/0.7	44.1/8.6	59.1/90.5
Nazar ⁴⁵ (2012)	CS; 4	10	24/30	55	7/17	40	3	20/24	0.75	_	/8.47	
McShane ⁴¹ (2006)	CS; 4	12	55/61	49	30/25	9	2.3	44/55	_	_		
$Grundberg^{22}$ (2000)	CS; 4	10	30/32	43	13/17	18	2.17	27/30	_	_		
Chalian ¹⁰ (2021)	CS; 4	12	37/37	51.3	15/22	>6	1.45	33/37	_		56.2/14.5	_
Lee ³⁶ (2018)	RCT; 2	Low	22/22	51.59 ± 5.75	8/14	23.91	2	21/22	_	7.27/1.5	60/25	53.9/95.7
Panthi ⁵⁴ (2017)	CS; 4	11	50/50	42.2	18/32	9.3	1	40/50	_	_	_	_
Radwan ⁵⁶ (2008)	PC; 3	20^b	27/27	39	18/9	18.26	1	21/27	_	3.5/0.6		_
Dunkow ¹⁶ (2004)	RCT; 2	Low	23/23	46	11/12	—	1	24/24	0.5	—	$70^{c}/49^{c}$	—

TABLE 2Characteristics of Studies Using the Percutaneous Approach for Lateral Epicondylitis $(n = 13 \text{ Studies})^a$

^aData are reported as the mean or mean \pm SD unless otherwise indicated. Dashes indicate data not reported. CS, case series; F, female; LOE, level of evidence; M, male; PC, prospective cohort; Postop, postoperative; Preop, preoperative; RCC, retrospective case control; RCT, randomized controlled trial; RoB, risk of bias; RTW, return to work; VAS, visual analog scale.

^bComparative study.

^cMedian.

and percutaneous) in terms of functional outcome (DASH), pain intensity (VAS), and patient satisfaction at 1-year follow-up. A retrospective study by Szabo et al⁶⁷ that compared functional outcomes in patients treated with open, arthroscopic, and percutaneous release reported similar functional outcomes and VAS scores after 48 months of follow-up in the 3 different groups. A systematic review by Moradi et al⁴² comparing open and arthroscopic surgery in LE found no significant differences in VAS and DASH scores, time to return to work, and patient satisfaction, although the arthroscopic approach had a lower complication rate. Paksoy et al⁵³ reported lower overall complication rates, shorter rehabilitation, faster wound healing, less postoperative pain, and earlier return to work and sports activities with the arthroscopic technique. Othman⁴⁹ showed no significant difference in functional outcomes in patients treated with the arthroscopic and percutaneous release (DASH score: 24 vs 20, respectively

 TABLE 3

 Characteristics of Studies Using the Arthroscopic Approach for Lateral Epicondylitis $(n = 22 \text{ Studies})^a$

											Score, Preop Postop	/
First Author (Year)	Study Design; LOE	MINORS or Cochrane RoB Score	Patients/ Elbows, n	Age, Years	Sex, M/F, n	Onset, Months	Follow-up, Years	Success Rate	RTW, Months	VAS Pain	DASH	MEPS
Fahmy ²⁰ (2022)	PCS; 4	14	22/22	34.6	17/5	10.8	5	22/22	3.9	7.86/0.79	_	57.1/95.6
Behazin ⁷ (2021)	PCS; 4	14	11/11	42 ± 6.8	3/8	18	1	10/11	_	7/2.2	56/15	56/90
Jeon ²⁴ (2020)	CS; 4	13	22/22	51.2	15/7	16.2	2.45	22/22	2.33	7.5/2.5	54.5/3.6	51.9/84.3
Paksoy ⁵³ (2021) ^c	CS; 4	13	(a) 18/18	(a) 46	(a) 46%	(a) 20	(a) 5.16	(a) 17/18	(a) 1.63	(a) 7.3/1.5	(a) 61/13	_
			(b) 20/20	(b) 43	(b) 48%	(b) 20	(b) 5	(b) 19/20	(b) 1.63	(b) 7.2/1.5	(b) 62/12	
Sochol ⁶¹ (2019)	Technical report; 4	9	35/35	46.2 ± 9.9	25/10	_	9.2	25/35	_	_	—	_
Nascimento ⁴⁴ (2017)	PCS; 4	14	104/104	46.9	71/33	25	2.86	99/104	_	7.6/3.3	48.9/21.24	_
Clark ¹¹ (2018)	RCT; 2	Low	32/32	45.6 ± 9.8	22/16	_	1	20/30	_	6.42/2.69	52.6/23.5	_
Lee ³⁶ (2018)	RCT; 2	Low	24/24	51.25	11/13	26.17	2	19/24	_	7.33/1.41	55/20	55.2/95.4
Soeur ⁶² (2016)	PCS; 4	12	35/39	48 ± 8.4	20/15	18	Median: 4	28/39	1.25	_	-/15.9	_
$\mathrm{Solheim}^{64}~(2016)^d$	RCC; 4	19^b	(c) 204/204	(c) 46	(c) 23/23	(c) 24	(c) 4.58	(c) 188/204	(c) 1.63	(c) 7.4/1.5	(c) 60/11	_
			(d) 79/79	(d) 47	(d) 23/24	(d) 24	(d) 4.67	(d) 71/79	$(d) \ 1.167$	(d) 7.2/1.5	(d) 60/12	
Ertem ¹⁹ (2015)	PCS; 4	14	29/29	46	14/15	_	1.7	21/28	_	_	81.1/34.7	48.5/101.2
Oki ⁴⁸ (2014)	PCS; 4	12	23/23	49	5/18	34	2	21/22	2	4.7/1.35	32/15	_
Babaqi ³ (2014)	CS; 4	14	31/33	33.7	20/11	16.3	1.2	29/31	0.267	8.64/1.48	24.46/4.81	61.82/94.1
Othman ⁴⁹ (2011)	PC; 3	22^b	14/14	42	8/6	>6	1	13/14	0.5-1	9.1/2	72/48	_
Lattermann ³⁵ (2010)	CS; 4	10	36/36	42	24/12	19	3.5	28/32	1.133	8.5/1.9	—	-/11.1
Grewal ²¹ (2009)	CS; 4	13	36/36	45.3	20/16	30	3.5	30/36	4.3	—	—	-/78.6
Wada ⁶⁸ (2009)	CS; 4	13	18/18	54	9/9	6	2.3	15/18	0.8	5.95/0.6	/10.6	_
Baker ⁴ (2008)	PCS; 4	11	30/30	43	19/11	14.4	10.83	29/30	_	/0.9835	—	-/11.7
$Cummins^{14}$ (2006)	PCS; 4	14	18/18	43.2	13/5	13.6	1.8	16/18	—	8.6/2.2	—	—
$Jerosch^{27}$ (2006)	CS; 4	11	20/20	45.3	13/7	>6	1.8	17/20	0.733	6.267/0.9	—	-/10.9
Mullett ⁴³ (2005)	CS; 4	13	30/30	46	16/14	>9	2	28/30	0.25	_	_	_
Owens ⁵⁰ (2001)	CS; 4	10	12/12	49.9	12/4	31.7	2	12/12	0.2	/1.8	_	_

 a Data are reported as the mean or mean \pm SD unless otherwise indicated. Dashes indicate data not reported. CS, case series; DASH, Disabilities of the Arm, Shoulder and Hand; F, female; LOE, level of evidence; M, male; MEPS, Mayo Elbow Performance Score; PC, prospective cohort; PCS, prospective case series; Postop, postoperative; Preop, preoperative; RC, retrospective cohort; RCC, retrospective case control; RCT, randomized controlled trial; RoB, risk of bias; RTW, return to work; VAS, visual analog scale.

^bComparative study.

 c Group (a) underwent arthroscopic lateral capsular resection with extensor carpi radialis brevis debridement; group (b) underwent arthroscopic lateral capsular resection alone.

^dGroup (c) underwent arthroscopic tenotomy; group (d) underwent arthroscopic debridement.

[P = .5]; reduction in VAS pain: 2 vs 2.1 points, respectively [P = .16]). These findings are comparable to our results, which showed a slight difference in the success rate of percutaneous and arthroscopic approaches (91% vs 91.9%).

Several studies failed to find the superiority of the arthroscopic approach to the open approach which were found in the current study.^{32,34} Kwon et al³⁴ also found that the Nirschl technique provided superior pain relief when compared with arthroscopic surgery despite a small effect size. Kim et al³² showed that the open surgery group had better grip strength and VAS score when compared with the arthroscopic group. We believe that the smaller effect size and sample size were the reasons for having a different conclusion from the present meta-analysis.³⁴

Traditionally, the aim of surgery for a refractory case of LE is to resect or release the degenerative tissue. Incomplete identification of the targeted area may cause incomplete resection of the degenerative tissue.^{12,25} Identifying the origin of ECRB as the targeted pathologic tissue is essential to achieve adequate resection. Arthroscopic surgery is advantageous because it allows surgeons to resect capsular pathology⁴ and proceed with the debridement of

pathologic ECRB. Moreover, the arthroscopic approach may facilitate the evaluation of elbow instability, which may coexist with LE.^{29,47} Ultimately, the arthroscopic approach also allows the surgeon to evaluate concomitant intra-articular pathology, which is not uncommon in refractory LE.^{24,25,26,30,31}

Strengths and Limitations

The present meta-analysis involved an extensive search, which was followed by the quantitative analysis of large number of participants (n = 1941 elbows) from 43 highquality studies. The results of the present meta-analysis can be generalized to the larger population because of the longer follow-up duration compared with that of the body of the published literature. Despite these strengths, the present meta-analysis reported variations in study outcomes between studies that showed moderate (arthroscopic and percutaneous surgery) to high heterogeneity (open surgery). Secondary data showed differences in surgical technique, duration of follow-up, and the variation in outcome measurement tools, which might contribute to the

Α	Studies	Esti	mate (95	5% CI)	Ev/Trt						
	Lee 2021		(0.921,								
	Clark 2018		(0.921,			_					
	Solheim 2013		(0.921,					-			
	Dwyer 2010		(0.861,								
	Coleman 2009		(0.795,								
	Dunn 2008		(0.761,		77/92						
	Svernlov 2006		(0.356,								
	Rubenthaler 2005		(0.336,				-		-		
	Dunkow 2004		(0.416,								_
	Rosenberg 2002		(0.606,						_		-
	Leppilahti 2001		(0.575,								_
	Lepphanti 2001	0.741	(0.575,	0.900)	20/21				-		
	Overall (12=86.78%, P< 0.001)	0.827	(0.756,	0.898)	494/591						-
						0.4	0.5	0.6 0	.7 0).8 (0.9 1
_								Proportio			
В	Studies	Esti	mate (95	5% CI)	Ev/Trt						
	Ang 2021		(0.907,		19/19					1	
	Yigit 2020		(0.778,		36/41						
	Suzuki 2020		(0.748,		31/36						
	Barnes 2014		(0.606,		15/19				-		
	Nazar 2012				20/24			-	-		
	McShane 2006		(0.684, (0.694,		44/55			-			
	Grundberg 2000		(0.793,		27/30			-		-	
	Chalian 2021		(0.793,		33/37						
			(0.911,								
	Seng 2015		(0.911,		20/20				_		_
	Lee 2017 Panthi 2016				21/22 46/50					_	-
	Radwan 2008		(0.845,		21/27			_		-	
	Dunkow 2004				21/2/ 24/24			-			
	Dulikow 2004	0.900	(0.925,	1.000)	24/24						
	Overall (12=49.41%, P=0.022)		(0.873,	0.946)	357/404				-	\Leftrightarrow	-
			(0.873,	0.946)	357/404		0.7	0.8	-	0.9	-
C	Overall (<i>I</i> ² =49.41%, P=0.022)		(0.873,	0.946)	357/404		0.7	0.8 Proportic	 on	0.9	-
С		0.910	(0.873, mate (95		357/404 Ev/Trt		0.7		 on	0.9	1
С	Overall (<i>I</i> ² =49.41%, P=0.022)	0.910 Esti		5% CI)			0.7		 Dn	0.9	
С	Overall (/²=49.41%, P=0.022) Studies	0.910 Esti 0.978	mate (95	5% CI) 1.000)	Ev/Trt		0.7		 on	0.9	
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022	0.910 Esti 0.978 0.909	mate (95 (0.919,	5% CI) 1.000) 1.000)	Ev/Trt 22/22		0.7		 on	0.9	
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020	0.910 Esti 0.978 0.909 0.978	mate (95 (0.919, (0.739,	5% CI) 1.000) 1.000) 1.000)	Ev/Trt 22/22 10/11		0.7		 on	0.9	>
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020	0.910 Esti 0.978 0.909 0.978 0.947	mate (95 (0.919, (0.739, (0.919,	5% CI) 1.000) 1.000) 1.000) 1.000)	Ev/Trt 22/22 10/11 22/22		0.7		 20	0.9	
C	Overall (/2=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018	0.910 Esti 0.978 0.909 0.978 0.947 0.986	mate (95 (0.919, (0.739, (0.919, (0.876,	5% CI) 1.000) 1.000) 1.000) 1.000) 1.000)	Ev/Trt 22/22 10/11 22/22 36/38		0.7		 20	0.9	
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498,</pre>	1.000) 1.000) 1.000) 1.000) 1.000) 0.993) 0.835)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30		0.7		- m	0.9	
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Paksoy 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629,</pre>	5% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.835) 0.954)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24		0.7		- nn 	0.9	
C	Overall (J2=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016	0.910 Esti 0.978 0.978 0.978 0.947 0.986 0.952 0.667 0.792 0.718	<pre>mate (95 (0.919, (0.739, (0.919, (0.919, (0.948, (0.941, (0.9911, (0.498, (0.629, (0.577,))))))))))))))))))))))))))))))))))</pre>	5% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.835) 0.954) 0.859)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39		0.7		- on 		
С	Overall (J2=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629, (0.577, (0.883,</pre>	5% CI) 1.000) 1.000) 1.000) 0.993) 0.835) 0.954) 0.859) 0.948)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283		0.7		- on 	0.9	= 1 - - - - - - - - - - - - - - - - - -
C	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015	0.910 Esti 0.978 0.909 0.978 0.986 0.952 0.667 0.792 0.718 0.915 0.750	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629, (0.577, (0.883, (0.590,</pre>	5% CI) 1.000) 1.000) 1.000) 0.993) 0.835) 0.954) 0.859) 0.948) 0.940)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28		0.7			0.9	······································
С	Overall (/2=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014	0.910 Esti 0.978 0.909 0.978 0.986 0.952 0.667 0.792 0.718 0.915 0.750 0.955	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629, (0.629, (0.863, (0.590, (0.868,</pre>	5% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.948) 0.948) 0.940) 1.000)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22		0.7		 on 	0.9	
C	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014	0.910 Esti 0.978 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.955 0.935	<pre>mate (95 (0.919, (0.739, (0.919, (0.919, (0.948, (0.941, (0.498, (0.629, (0.577, (0.883, (0.590, (0.596, (0.849,))))))))))))))))))))))))))))))))))))</pre>	5% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.948) 0.948) 0.940) 1.000) 1.000)	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31		0.7			0.9	
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Soli 2014 Babaqi 2014 Othman 2011	0.910 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.955 0.935 0.929	<pre>mate (95 (0.919, (0.739, (0.919, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.590, (0.863, (0.849, (0.794,)</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.948) 0.910) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.750 0.935 0.935 0.929 0.875	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629, (0.577, (0.883, (0.590, (0.868, (0.964, (0.944, (0.794, (0.760,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.835) 0.954) 0.859) 0.948) 0.910) 1.000) 1.000) 1.000) 0.990)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.915 0.955 0.925 0.925 0.935 0.929 0.875 0.833	<pre>mate (95 (0.919, (0.739, (0.919, (0.876, (0.948, (0.911, (0.498, (0.629, (0.577, (0.883, (0.590, (0.868, (0.590, (0.868, (0.794, (0.760, (0.712,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.855) 0.948) 0.910) 1.000) 1.000) 1.000) 0.990) 0.955)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/28 21/28 21/22 29/31 13/14 28/32 30/36		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.915 0.915 0.925 0.925 0.925 0.925 0.833 0.833	<pre>mate (95 (0.919, (0.739, (0.919, (0.9476, (0.941, (0.498, (0.629, (0.590, (0.868, (0.849, (0.794, (0.760, (0.712, (0.661,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 0.993) 0.935) 0.954) 0.959) 0.948) 0.910) 1.000) 1.000) 1.000) 1.000) 0.995) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18		0.7				
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Baker 2008	0.910 Esti 0.978 0.909 0.978 0.986 0.986 0.952 0.667 0.792 0.718 0.915 0.750 0.935 0.935 0.935 0.935 0.929 0.833 0.833 0.833 0.967	<pre>mate (95 (0.919, (0.739, (0.919, (0.917, (0.948, (0.941, (0.498, (0.629, (0.577, (0.883, (0.849, (0.794, (0.760, (0.712, (0.661, (0.902,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.948) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30		0.7				
С	Overall (/²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Baker 2008 Jerosch 2006	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.955 0.935 0.935 0.935 0.929 0.875 0.833 0.833 0.967 0.850	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.597, (0.583, (0.594, (0.794, (0.794, (0.760, (0.712, (0.661, (0.902, (0.694,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Baker 2008 Jerosch 2006 Cummins 2006	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.792 0.718 0.915 0.935 0.935 0.935 0.929 0.875 0.833 0.967 0.850 0.889	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.590, (0.590, (0.794, (0.794, (0.760, (0.712, (0.661, (0.902, (0.694, (0.744,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20 16/18		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Baker 2008 Jerosch 2006 Cummins 2006 Mullet 2005	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.750 0.935 0.929 0.875 0.833 0.967 0.833 0.967 0.889 0.933	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.868, (0.949, (0.794, (0.760, (0.712, (0.661, (0.902, (0.944, (0.844,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.955) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20 16/18 28/30		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Wada 2009 Baker 2008 Jerosch 2006 Cummins 2006 Mullet 2005 Owens 2001	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.935 0.935 0.935 0.933 0.833 0.967 0.850 0.889 0.933 0.962	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.590, (0.590, (0.629, (0.794, (0.794, (0.760, (0.704, (0.602, (0.694, (0.744, (0.844, (0.857,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20 16/18 28/30 12/12		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Baker 2008 Jerosch 2006 Cummins 2006 Mullet 2005	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.935 0.935 0.935 0.933 0.833 0.967 0.850 0.889 0.933 0.962	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.590, (0.590, (0.629, (0.794, (0.794, (0.760, (0.704, (0.602, (0.694, (0.744, (0.844, (0.857,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20 16/18 28/30 12/12		0.7				
C	Overall (J²=49.41%, P=0.022) Studies Fahmy 2022 Behazin 2020 Jeon 2020 Paksoy 2020 Sochol 2019 Nascimento 2018 Clark 2018 Lee 2017 Soeur 2016 Solheim 2016 Ertem 2015 Oki 2014 Babaqi 2014 Othman 2011 Lattermann 2010 Grewal 2009 Wada 2009 Wada 2009 Baker 2008 Jerosch 2006 Cummins 2006 Mullet 2005 Owens 2001	0.910 Esti 0.978 0.909 0.978 0.947 0.986 0.952 0.667 0.792 0.718 0.915 0.935 0.935 0.935 0.933 0.833 0.967 0.850 0.889 0.933 0.962	<pre>mate (95 (0.919, (0.739, (0.919, (0.948, (0.948, (0.629, (0.577, (0.883, (0.590, (0.590, (0.590, (0.629, (0.794, (0.794, (0.760, (0.704, (0.602, (0.694, (0.744, (0.844, (0.857,</pre>	<pre>% CI) 1.000) 1.000) 1.000) 1.000) 0.993) 0.954) 0.954) 0.910) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000) 1.000)</pre>	Ev/Trt 22/22 10/11 22/22 36/38 35/35 99/104 20/30 19/24 28/39 259/283 21/28 21/22 29/31 13/14 28/32 30/36 15/18 29/30 17/20 16/18 28/30 12/12	0.5	0.7				

Figure 3. Forest plots of the success rates for the (A) open approach, (B) percutaneous approach, and (C) arthroscopic approach. Ev/Trt, event/treated.




Figure 4. Graphs showing results of pre- versus postoperative functional scores according to surgical approach: (A) the DASH score and (B) the MEPS. DASH, Disabilities of the Arm, Shoulder and Hand; MEPS, Mayo Elbow Performance Score.

high heterogeneity of the open surgery group. In addition, we were unable to account for the variations regarding the perioperative protocol, such as physical therapy within each group, that may be present.

CONCLUSION

Open, percutaneous, and arthroscopic surgeries resulted in favorable outcomes in managing refractory LE. Arthroscopic surgery had a slightly higher success rate and functional outcome when compared with open and percutaneous surgeries, based on our systematic review here; however, higher-level studies are needed to draw strong conclusions.

REFERENCES

- Ang BFH, Mohan PC, Png MA, et al. Ultrasonic percutaneous tenotomy for recalcitrant lateral elbow tendinopathy: clinical and sonographic results at 90 months. *Am J Sports Med.* 2021;49(7):1854-1860.
- Arem Lim KS, Mile Ini EN, Amien Orestier DF, et al. Methodological Index for Non-Randomized Studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712-716.
- Babaqi AA, Kotb MM, Said HG, AbdelHamid MM, ElKady HA, ElAssal MA. Short-term evaluation of arthroscopic management of tennis elbow; including resection of radio-capitellar capsular complex. J Orthop. 2014;11(2):82-86.
- Baker CL, Baker CL. Long-term follow-up of arthroscopic treatment of lateral epicondylitis. Am J Sports Med. 2008;36(2):254-260.
- Baker CL, Murphy KP, Gottlob CA, Curd DT. Arthroscopic classification and treatment of lateral epicondylitis: two-year clinical results. J Shoulder Elbow Surg. 2000;9(6):475-482.
- Barnes DE, Beckley JM, Smith J. Percutaneous ultrasonic tenotomy for chronic elbow tendinosis: a prospective study. *J Shoulder Elbow* Surg. 2015;24(1):67-73.
- Behazin M, Kachooei AR. Arthroscopic recession technique in the surgery of tennis elbow by sharp cutting the extensor carpi radialis brevis (ECRB) tendon origin. Arch Bone Jt Surg. 2021;9(2):174-179.

- Buchanan BK, Varacallo M. Lateral epicondylitis (tennis elbow). In StatPearls [Internet]. StatPearls Publishing. January 2023.
- Burn MB, Mitchell RJ, Liberman SR, Lintner DM, Harris JD, McCulloch PC. Open, arthroscopic, and percutaneous surgical treatment of lateral epicondylitis: a systematic review. *Hand* (N Y). 2018;13(3):264-274.
- Chalian M, Nacey NC, Rawat U, et al. Ultrasound-guided percutaneous needle tenotomy using Tenex system for refractory lateral epicondylitis; short and long-term effectiveness and contributing factors. *Skeletal Radiol*. 2021;50(10):2049-2057.
- Clark T, McRae S, Leiter J, Zhang Y, Dubberley J, MacDonald P. Arthroscopic versus open lateral release for the treatment of lateral epicondylitis: a prospective randomized controlled trial. *Arthroscopy*. 2018;34(12):3177-3184.
- Cohen MS, Romeo AA, Hennigan SP, Gordon M. Lateral epicondylitis: anatomic relationships of the extensor tendon origins and implications for arthroscopic treatment. *J Shoulder Elbow Surg.* 2008;17(6):954-960.
- Coleman B, Quinlan JF, Matheson JA. Surgical treatment for lateral epicondylitis: a long-term follow-up of results. J Shoulder Elbow Surg. 2010;19(3):363-367.
- Cummins CA. Lateral epicondylitis: in vivo assessment of arthroscopic debridement and correlation with patient outcomes. *Am J Sports Med*. 2006;34(9):1486-1491.
- 15. Cutts S, Gangoo S, Modi N, Pasapula C. Tennis elbow: a clinical review article. *J Orthop*. 2019;17:203-207.
- Dunkow PD, Jatti M, Muddu BN. A comparison of open and percutaneous techniques in the surgical treatment of tennis elbow. J Bone Joint Surg Br. 2004;86(5):701-704.
- Dunn JH, Kim JJ, Davis L, Nirschl RP. Ten- to 14-year follow-up of the Nirschl surgical technique for lateral epicondylitis. *Am J Sports Med.* 2008;36(2):261-266.
- Dwyer AJ, Govindaswamy R, Elbouni T, Chambler AFW. Are "knife and fork" good enough for day case surgery of resistant tennis elbow? *Int Orthop.* 2010;34(1):57-61.
- Ertem K. Functional outcomes of arthroscopic treatment method of lateral epicondylitis. Acta Orthop Traumatol Turc. 2015;9(5):471-477.
- Fahmy FS, ElAttar M, Salem HF. Hand-grip strength and return to heavy manual work at a mean 5-year follow-up after arthroscopic release of recalcitrant lateral epicondylitis. Orthop J Sports Med. 2022;10(2):23259671221078586.
- Grewal R, MacDermid JC, Shah P, King GJW. Functional outcome of arthroscopic extensor carpi radialis brevis tendon release in chronic lateral epicondylitis. *J Hand Surg Am.* 2009;34(5):849-857.

- Grundberg AB, Dobson JF. Percutaneous release of the common extensor origin for tennis elbow. *Clin Orthop Relat Res.* 2000; 376:137-140.
- 23. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine. Accessed April 12, 2022. https://www.cebm.ox.ac.uk/resources/lev els-of-evidence/ocebm-levels-of-evidence
- 24. Jeon IH, Kwak JM, Zhu B, et al. Arthroscopic modified Bosworth procedure for refractory lateral elbow pain with radiocapitellar joint snapping. *Orthop J Sports Med*. 2020;8(6):232596712092992.
- Jeon IH, Liu H, Nanda A, et al. Systematic review of the surgical outcomes of elbow plicae. Orthop J Sports Med. 2020;8(10): 232596712095516.
- Jeon JY, Lee MH, Jeon IH, Chung HW, Lee SH, Shin MJ. Lateral epicondylitis: associations of MR imaging and clinical assessments with treatment options in patients receiving conservative and arthroscopic managements. *Eur Radiol*. 2018;28(3):972-981.
- Jerosch J, Schunck J. Arthroscopic treatment of lateral epicondylitis: indication, technique and early results. *Knee Surg Sports Traumatol Arthrosc.* 2006;14(4):379-382.
- Khashaba A. Nirschl tennis elbow release with or without drilling. Br J Sports Med. 2001;35(3):200.
- 29. Kholinne E, Liu H, Kim H, Kwak JM, Koh KH, Jeon IH. Systematic review of elbow instability in association with refractory lateral epicondylitis: myth or fact? *Am J Sports Med*. 2021;49(9):2542-2550.
- Kholinne E, Nanda A, Liu H, et al. The elbow plica: a systematic review of terminology and characteristics. *J Shoulder Elbow Surg.* 2021;30(5):e185-e198.
- Kholinne E, Singjie LC, Marsetio AF, Kwak JM, Jeon IH. Return to physical activities after arthroscopic rotator cuff repair: a systematic review and meta-analysis. *Eur J Orthop Surg Traumatol*. 2023;33(6):1-10.
- Kim DS, Chung HJ, Yi CH, Kim SH. Comparison of the clinical outcomes of open surgery versus arthroscopic surgery for chronic refractory lateral epicondylitis of the elbow. *Orthopedics*. 2018;41(4):237-247.
- Kim GM, Yoo SJ, Choi S, Park YG. Current trends for treating lateral epicondylitis. *Clin Shoulder Elb*. 2019;22(4):227-234.
- Kwon BC, Kim JY, Park KT. The Nirschl procedure versus arthroscopic extensor carpi radialis brevis débridement for lateral epicondylitis. J Shoulder Elbow Surg. 2017;26(1):118-124.
- Lattermann C, Romeo AA, Anbari A, et al. Arthroscopic debridement of the extensor carpi radialis brevis for recalcitrant lateral epicondylitis. J Shoulder Elbow Surg. 2010;19(5):651-656.
- Lee JH, Park I, Hyun HS, Shin SJ. A comparison of radiofrequencybased microtenotomy and arthroscopic release of the extensor carpi radialis brevis tendon in recalcitrant lateral epicondylitis: a prospective randomized controlled study. *Arthroscopy*. 2018;34(5):1439-1446.
- Lee S, Hong IT, Lee S, Kim TS, Jung K, Han SH. Long-term outcomes of the modified Nirschl technique for lateral epicondylitis: a retrospective study. *BMC Musculoskelet Disord*. 2021;22(1):205.
- 38. Leppilahti J, Raatikainen T, Pienimäki T, Hänninen A, Jalovaara P. Surgical treatment of resistant tennis elbow. A prospective, randomised study comparing decompression of the posterior interosseous nerve and lengthening of the tendon of the extensor carpi radialis brevis muscle. Arch Orthop Trauma Surg. 2001;121(6):329-332.
- Lo MY, Safran MR. Surgical treatment of lateral epicondylitis: a systematic review. *Clin Orthop Relat Res.* 2007;463:98-106.
- López-Alameda S, Varillas-Delgado D, De Felipe-Gallego J, González-Granados MG, Hernández-Castillejo LE, García-de Lucas F. Arthroscopic surgery versus open surgery for lateral epicondylitis in an active work population: a comparative study. *J Shoulder Elbow Surg.* 2022;31(5):984-990.
- McShane JM, Nazarian LN, Harwood MI. Sonographically guided percutaneous needle tenotomy for treatment of common extensor tendinosis in the elbow. J Ultrasound Med. 2006;25(10):1281-1289.
- 42. Moradi A, Pasdar P, Mehrad-Majd H, Ebrahimzadeh MH. Clinical outcomes of open versus arthroscopic surgery for lateral

epicondylitis, evidence from a systematic review. Arch Bone Jt Surg. 2019;7(2):91-104.

- Mullett H, Sprague M, Brown G, Hausman M. Arthroscopic treatment of lateral epicondylitis: clinical and cadaveric studies. *Clin Orthop Relat Res.* 2005;439:123-128.
- Nascimento AT do, Claudio GK. Arthroscopic surgical treatment of recalcitrant lateral epicondylitis—a series of 47 cases?. *Rev Bras Ortop* (Sao Paulo). 2017;52(1):46-51.
- Nazar M, Lipscombe S, Morapudi S, et al. Percutaneous tennis elbow release under local anaesthesia. Open Orthop J. 2012;6(1):129-132.
- Nirschl RP, Pettrone FA. Tennis elbow. The surgical treatment of lateral epicondylititis. J Bone Joint Surg Am. 1979;61(6):832-839.
- O'Brien MJ, Savoie FH. Arthroscopic and open management of posterolateral rotatory instability of the elbow. *Sports Med Arthrosc Rev.* 2014;22(3):194-200.
- Oki G, Iba K, Sasaki K, Yamashita T, Wada T. Time to functional recovery after arthroscopic surgery for tennis elbow. *J Shoulder Elbow Surg.* 2014;23(10):1527-1531.
- Othman AMA. Arthroscopic versus percutaneous release of common extensor origin for treatment of chronic tennis elbow. Arch Orthop Trauma Surg. 2011;131(3):383-388.
- Owens BD, Murphy KP, Kuklo TR. Arthroscopic release for lateral epicondylitis. Arthroscopy. 2001;17(6):582-587.
- Oztuna V, Milcan A, Eskandari MM, Kuyurtar F. Percutaneous extensor tenotomy in patients with lateral epicondylitis resistant to conservative treatment. Article in Turkish. Acta Orthop Traumatol Turc. 2002;36(4):336-340.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- Paksoy AE, Laver L, Tok O, Ayhan C, Kocaoglu B. Arthroscopic lateral capsule resection is enough for the management of lateral epicondylitis. *Knee Surg Sports Traumatol Arthrosc.* 2021;29(6):2000-2005.
- Panthi S, Khatri K, Kharel K, et al. Outcome of percutaneous release of tennis elbow: a non-randomized controlled trial study. *Cureus*. 2017;9(1):e952.
- Pierce TP, Issa K, Gilbert BT, et al. A systematic review of tennis elbow surgery: open versus arthroscopic versus percutaneous release of the common extensor origin. *Arthroscopy*. 2017;33(6):1260-1268.
- Radwan YA, ElSobhi G, Badawy WS, Reda A, Khalid S. Resistant tennis elbow: shock-wave therapy versus percutaneous tenotomy. *Int Orthop.* 2008;32(5):671-677.
- Risk of Bias 2 Cochrane Review Group Starter Pack Risk of Bias 2 CRG Starter Pack 2. Published online May 2022. Accessed April 12, 2022. https://methods.cochrane.org/file/rob-2-starter-packcochrane-reviewspdf
- Rosenberg N, Henderson I. Surgical treatment of resistant lateral epicondylitis. Arch Orthop Trauma Surg. 2002;122(9):514-517.
- Rubenthaler F, Wiese M, Senge A, Keller L, Hermann Wittenberg R. Long-term follow-up of open and endoscopic Hohmann procedures for lateral epicondylitis. *Arthroscopy*. 2005;21(6):684-690.
- Seng C, Mohan PC, Koh SBJ, et al. Ultrasonic percutaneous tenotomy for recalcitrant lateral elbow tendinopathy. *Am J Sports Med*. 2016;44(2):504-510.
- Sochol KM, London DA, Rothenberg ES, Hausman MR. Arthroscopic treatment of lateral elbow pain mimicking lateral epicondylitis: longterm follow-up of a unique surgical protocol. *Tech Hand Up Extrem Surg.* 2019;23(1):27-30.
- Soeur L, Desmoineaux P, Devillier A, Pujol N, Beaufils P. Outcomes of arthroscopic lateral epicondylitis release: should we treat earlier? *Orthop Traumatol Surg Res.* 2016;102(6):775-780.
- Solheim E, Hegna J, Øyen J. Arthroscopic versus open tennis elbow release: 3- to 6-year results of a case-control series of 305 elbows. *Arthroscopy*. 2013;29(5):854-859.
- Solheim E, Hegna J, Øyen J, Inderhaug E. Arthroscopic treatment of lateral epicondylitis: tenotomy versus debridement. *Arthroscopy*. 2016;32(4):578-585.

- Suzuki T, Iwamoto T, Matsumura N, Nakamura M, Matsumoto M, Sato K. Percutaneous tendon needling without ultrasonography for lateral epicondylitis. *Keio J Med*. 2020;69(2):37-42.
- Svernlöv B, Adolfsson L. Outcome of release of the lateral extensor muscle origin for epicondylitis. *Scand J Plast Reconstr Surg Hand Surg*. 2006;40(3):161-165.
- 67. Szabo SJ, Savoie FH, Field LD, Ramsey JR, Hosemann CD. Tendinosis of the extensor carpi radialis brevis: an evaluation of three

methods of operative treatment. J Shoulder Elbow Surg. 2006; 15(6):721-727.

- Wada T, Moriya T, Iba K, et al. Functional outcomes after arthroscopic treatment of lateral epicondylitis. *J Orthop Sci.* 2009;14(2):167-174.
- Yigit Ş. Medium-term results after treatment of percutaneous tennis elbow release under local anaesthesia. Acta Biomed. 2020;91(2): 305-309.